Aurora Cannabis

Aurora Cannabis reported net revenue of CAD 321 million for fiscal 2026 (+11%) and adjusted EBITDA of CAD 54 million (+32%). Growth was driven by international expansion and a focus on higher-margin medical cannabis; international markets accounted for 55% of revenue. The company is debt-free and holds CAD 165 million in cash, and it forecasts Q1 FY2027 EPS of -0.08 USD and revenue of USD 54.94 million. The stock fell 2.96% after the results were released. » Mais em de.investing.com

Aurora Cannabis will release results for the quarter ended 31/03/2026 on 11/06/2026. Five analysts expect an average loss of -0.058 CAD per share (prior year: -0.350 CAD) and six analysts forecast revenue of 75.7 million CAD, about 16.4% below last year’s 90.5 million CAD. For the past fiscal year, five analysts estimate an average loss of -1.197 CAD per share and six analysts see annual revenue at 358.4 million CAD (prior year: 343.3 million CAD). » Mais em finanzen.net

Aurora Cannabis will launch new medical cannabis products by June in Canada, Germany, Poland and Australia, including dried flower, pre-rolls and lozenges. In Germany the company will offer San Raf Pink OG Kush (25–27% THC) and Daily Special Lemon Sorbet (21% THC); Poland and Australia will also receive high‑potency strains and multi‑stage lozenge formulations. The products are manufactured in GMP‑certified facilities in Canada and Germany and are part of the company’s international “Medical‑First” strategy. Aurora has a market capitalization of about USD 207.74 million and recorded a 25% share price decline in the past year, while InvestingPro currently rates the stock as undervalued. » Mais em de.investing.com